Olav Engebråten
- Consultant, 1. aman.; Dr. med
- +47 97 66 62 50
Publications 2024
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol, 18 (8), 2042-2059
DOI 10.1002/1878-0261.13656, PubMed 38671580
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499
Publications 2023
Liver X receptors induce antiproliferative effects in basal-like breast cancer
Mol Oncol, 17 (10), 2041-2055
DOI 10.1002/1878-0261.13476, PubMed 37341140
MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients
Cancers (Basel), 15 (18)
DOI 10.3390/cancers15184662, PubMed 37760629
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
PLoS One, 18 (1), e0280507
DOI 10.1371/journal.pone.0280507, PubMed 36706086
Breast cancer patient-derived explant cultures recapitulate in vivo drug responses
Front Oncol, 13, 1040665
DOI 10.3389/fonc.2023.1040665, PubMed 36910663
Publications 2022
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1
DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388
Quantification of Tumor Hypoxia through Unsupervised Modelling of Consumption and Supply Hypoxia MR Imaging in Breast Cancer
Cancers (Basel), 14 (5)
DOI 10.3390/cancers14051326, PubMed 35267636
Publications 2021
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
Mol Oncol, 15 (8), 2026-2045
DOI 10.1002/1878-0261.12951, PubMed 33759347
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Nat Commun, 12 (1), 6427
DOI 10.1038/s41467-021-26018-z, PubMed 34741021
Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation
Proc Natl Acad Sci U S A, 118 (45)
DOI 10.1073/pnas.2100050118, PubMed 34737229
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016
Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
Nanomaterials (Basel), 11 (5)
DOI 10.3390/nano11051140, PubMed 33924869
Publications 2020
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909
Publications 2019
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat. Commun., 10, 5499
DOI 10.1038/s41467-019-13329-5
Publications 2018
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
J Natl Cancer Inst, 110 (6), 560-567
DOI 10.1093/jnci/djy018, PubMed 29659933
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
J Control Release, 293, 183-192
DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Genome Med, 10 (1), 92
DOI 10.1186/s13073-018-0601-y, PubMed 30497530
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
Oncoimmunology, 7 (11), e1457598
DOI 10.1080/2162402X.2018.1457598, PubMed 30377556
Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
Mol Oncol, 12 (9), 1540-1558
DOI 10.1002/1878-0261.12319, PubMed 29741811
Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
Cancer Lett, 439, 1-13
DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588
Publications 2017
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Metabolomics, 13 (4), 37
DOI 10.1007/s11306-017-1168-0
Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
Mol Imaging Biol, 19 (2), 271-279
DOI 10.1007/s11307-016-0998-x, PubMed 27541026
Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
Mol Oncol, 11 (10), 1361-1379
DOI 10.1002/1878-0261.12105, PubMed 28657165
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444
Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
Oncotarget, 8 (44), 76921-76934
DOI 10.18632/oncotarget.20217, PubMed 29100358
Publications 2016
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model
BMC Cancer, 16, 191
DOI 10.1186/s12885-016-2225-1, PubMed 26951085
Fatigue During and After Breast Cancer Therapy-A Prospective Study
J Pain Symptom Manage, 53 (3), 551-560
DOI 10.1016/j.jpainsymman.2016.09.011, PubMed 28042070
Publications 2015
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Br J Cancer, 113 (11), 1548-55
DOI 10.1038/bjc.2015.380, PubMed 26554649
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
Genes Dev, 29 (12), 1298-315
DOI 10.1101/gad.263202.115, PubMed 26080815
Publications 2014
pH-responsive nano carriers for doxorubicin delivery
Pharm Res, 32 (4), 1249-63
DOI 10.1007/s11095-014-1530-0, PubMed 25288014
In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts
J Magn Reson Imaging, 41 (3), 601-9
DOI 10.1002/jmri.24588, PubMed 24532410
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
Breast Cancer Res, 16 (1), R5
DOI 10.1186/bcr3597, PubMed 24447408
Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
Acta Oncol, 53 (8), 1086-92
DOI 10.3109/0284186X.2014.934398, PubMed 25017377
Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis
J Magn Reson Imaging, 40 (6), 1382-91
DOI 10.1002/jmri.24502, PubMed 24470360
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568
Publications 2013
Triple-negative breast cancer and the need for new therapeutic targets
Am J Pathol, 183 (4), 1064-1074
DOI 10.1016/j.ajpath.2013.05.033, PubMed 23920327
Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
Magn Reson Med, 71 (6), 1973-81
DOI 10.1002/mrm.24869, PubMed 23878023
Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
Nucl Med Mol Imaging, 47 (3), 173-80
DOI 10.1007/s13139-013-0211-y, PubMed 24900104
Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
Acta Oncol, 52 (7), 1566-72
DOI 10.3109/0284186X.2013.813634, PubMed 23984812
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
Clin Cancer Res, 20 (2), 404-12
DOI 10.1158/1078-0432.CCR-13-1865, PubMed 24192926
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
Breast Cancer Res, 15 (1), R16
DOI 10.1186/bcr3391, PubMed 23448424
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
J Magn Reson Imaging, 38 (5), 1043-53
DOI 10.1002/jmri.24079, PubMed 23908122
Publications 2012
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
Mol Oncol, 7 (1), 130-42
DOI 10.1016/j.molonc.2012.10.005, PubMed 23142657
Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
ISRN Oncol, 2012, 176789
DOI 10.5402/2012/176789, PubMed 22666610
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
PLoS One, 7 (9), e45492
DOI 10.1371/journal.pone.0045492, PubMed 23029050
Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts
Mol Oncol, 6 (4), 418-27
DOI 10.1016/j.molonc.2012.03.006, PubMed 22521242
Publications 2011
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Cancer Biol Ther, 12 (1), 47-58
DOI 10.4161/cbt.12.1.15714, PubMed 21508672
13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns
NMR Biomed, 24 (10), 1243-52
DOI 10.1002/nbm.1683, PubMed 21462378
In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts
J Magn Reson Imaging, 35 (5), 1098-107
DOI 10.1002/jmri.23507, PubMed 22170753
Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy
Mol Oncol, 5 (3), 224-41
DOI 10.1016/j.molonc.2011.04.001, PubMed 21536506
Publications 2010
Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging
Eur Radiol, 21 (6), 1188-99
DOI 10.1007/s00330-010-2020-3, PubMed 21127880
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
BMC Cancer, 10, 433
DOI 10.1186/1471-2407-10-433, PubMed 20716336
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
Pigment Cell Melanoma Res, 23 (3), 449-51
DOI 10.1111/j.1755-148X.2010.00690.x, PubMed 20236249
Publications 2009
Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
Br J Cancer, 101 (8), 1307-15
DOI 10.1038/sj.bjc.6605312, PubMed 19773757
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161
Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins
Anticancer Res, 29 (1), 131-7
PubMed 19331142
Publications 2007
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
J Gene Med, 9 (6), 440-51
DOI 10.1002/jgm.1036, PubMed 17410615
Publications 2006
Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines
Cancer Biol Ther, 5 (11), 1511-20
DOI 10.4161/cbt.5.11.3301, PubMed 17012835
Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus
J Gene Med, 8 (6), 707-18
DOI 10.1002/jgm.902, PubMed 16518880
Publications 2005
PCI-enhanced adenoviral transduction employs the known uptake mechanism of adenoviral particles
Cancer Gene Ther, 12 (5), 439-48
DOI 10.1038/sj.cgt.7700808, PubMed 15678152
Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers
Cancer Gene Ther, 12 (11), 864-72
DOI 10.1038/sj.cgt.7700852, PubMed 15891771
Publications 2004
Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme
J Neurosurg, 100 (2), 320-7
DOI 10.3171/jns.2004.100.2.0320, PubMed 15086240
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
Exp Cell Res, 294 (1), 130-9
DOI 10.1016/j.yexcr.2003.10.013, PubMed 14980508
Publications 2003
Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1
Clin Exp Metastasis, 20 (4), 301-9
DOI 10.1023/a:1024040718238, PubMed 12856717
Publications 2002
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
Int J Cancer, 97 (6), 846-52
DOI 10.1002/ijc.10137, PubMed 11857366
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)
Int J Oncol, 21 (3), 577-82
PubMed 12168102
Expression of extracellular matrix components in a highly infiltrative in vivo glioma model
Acta Neuropathol, 105 (1), 49-57
DOI 10.1007/s00401-002-0610-0, PubMed 12471461
Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
Int J Cancer, 97 (1), 28-33
DOI 10.1002/ijc.1564, PubMed 11774240
Publications 2001
Invasiveness in vitro and biological markers in human primary glioblastomas
J Neurooncol, 54 (1), 1-8
DOI 10.1023/a:1012565503958, PubMed 11763417
Publications 2000
Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats
Int J Cancer, 88 (6), 970-6
DOI 10.1002/1097-0215(20001215)88:6<970::aid-ijc21>3.0.co;2-q, PubMed 11093823
lacZ-neoR transfected glioma cells in syngeneic rats: growth pattern and characterization of the host immune response against cells transplanted inside and outside the CNS
Int J Cancer, 85 (2), 228-35
DOI 10.1002/(SICI)1097-0215(20000115)85:2<228::AID-IJC13>3.0.CO;2-9, PubMed 10629082
Publications 1999
Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats
Int J Cancer, 82 (2), 219-25
DOI 10.1002/(sici)1097-0215(19990719)82:2<219::aid-ijc12>3.0.co;2-#, PubMed 10389756
Growth of precultured human glioma specimens in nude rat brain
J Neurosurg, 90 (1), 125-32
DOI 10.3171/jns.1999.90.1.0125, PubMed 10413165
Expression of a novel factor in human breast cancer cells with metastatic potential
Cancer Res, 59 (18), 4675-80
PubMed 10493524
Publications 1998
[Use of antipsychotic drugs in a long-term care institution. Experiences with implementing clinical guidelines]
Tidsskr Nor Laegeforen, 118 (14), 2144-7
PubMed 9656807
Publications 1997
Role of high molecular weight extracellular matrix proteins in glioma cell migration
Neuropathol Appl Neurobiol, 23 (2), 102-12
DOI 10.1046/j.1365-2990.1997.8398083.x, PubMed 9160895
Publications 1996
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
DOI 10.1038/bjc.1996.181, PubMed 8611425
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res, 56 (23), 5490-8
PubMed 8968106
Publications 1995
[Emergency hospital admissions. A survey and consumer assessment of conditions in an emergency department admission office]
Tidsskr Nor Laegeforen, 115 (23), 2917-20
PubMed 7570518
[Primary health care and emergency admission of patients. What happened prior to admissions and how did the patients experience the primary health care system?]
Tidsskr Nor Laegeforen, 115 (23), 2913-6
PubMed 7570517
Publications 1994
[Diagnoses in medical and surgical patients. Experiences of a junior physician]
Tidsskr Nor Laegeforen, 114 (10), 1179-84
PubMed 8209314
Heterogeneous response to the growth factors [EGF, PDGF (bb), TGF-alpha, bFGF, IL-2] on glioma spheroid growth, migration and invasion
Int J Cancer, 56 (2), 255-61
DOI 10.1002/ijc.2910560219, PubMed 8314309
Leptomeningeal tissue: a barrier against brain tumor cell invasion
J Natl Cancer Inst, 86 (21), 1593-9
DOI 10.1093/jnci/86.21.1593, PubMed 7932823
Organ culture of a glioblastoma from a patient with an unusually long survival
Neurosurgery, 35 (3), 428-32; discussion 432-3
DOI 10.1227/00006123-199409000-00010, PubMed 7800134
Publications 1993
[Hypoplastic left heart syndrome]
Tidsskr Nor Laegeforen, 113 (30), 3770-1
PubMed 8278970
Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro
Int J Cancer, 53 (2), 209-14
DOI 10.1002/ijc.2910530206, PubMed 8381111
Publications 1992
Biology and experimental therapy of invasive glioma cellsin tissue culture: with emphasis on membrane related structures
The Gade Institute, Department of Pathology, University of Bergen, Bergen, 1 b.(flere pag.)
BIBSYS 931753201, ISBN 82-91304-01-7
Effects of high and low single dose irradiation on glioma spheroid invasion into normal rat brain tissue in vitro
Anticancer Res, 12 (5), 1501-6
PubMed 1444212
[Working conditions of medical students--medical students and research]
Tidsskr Nor Laegeforen, 112 (17), 2202-4
PubMed 1523657
[Research interest and recruitment potential--medical students and research]
Tidsskr Nor Laegeforen, 112 (17), 2205-7
PubMed 1523658
Publications 1991
Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line
Cancer Res, 51 (17), 4643-8
PubMed 1873810
Effect of alkyl-lysophospholipid on glioblastoma cell invasion into fetal rat brain tissue in vitro
Cancer Res, 51 (6), 1713-9
PubMed 1998962
Publications 1990
Interaction between human brain tumour biopsies and fetal rat brain tissue in vitro
Acta Neuropathol, 81 (2), 130-40
DOI 10.1007/BF00334501, PubMed 2082653
Invasive glioma cells in tissue culture
Anticancer Res, 10 (5A), 1135-51
PubMed 2241095